Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Alain Kaelin

Status and phase

Enrolling

Phase 4

Conditions

Idiopathic Parkinson's Disease (at Later Stage)

Treatments

Drug: Safinamide

Study type

Interventional

Funder types

Other

Identifiers

NCT03968744

NSI-SAF-001

Details and patient eligibility

About

Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Full description

Adult patients affected by PD and suffering from motor fluctuations will be screened for participation.

If the inclusion and exclusion criteria are met, the participant will enter in the baseline assessment phase and undergo 1 night baseline PSG and 1 week baseline actigraphy. The patient will then start the treatment with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will last for 10 weeks (maintenance phase). At week 12 (end of treatment), the questionnaires, actigraphy and PSG will be repeated. A safety follow-up visit is scheduled 4 weeks after study treatment completion.

The treatment will be continued thereafter in all patients if medically indicated.

Enrollment

23 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years old
Fluctuating idiopathic PD patients according to UK Brain bank Criteria
Hoehn and Year II to IV under treatment
Sleep disturbance with a Pittsburgh Sleep Quality Index (PSQI) > 5
Treatment with L-DOPA, alone or with other dopaminergic drugs, at a stable dose since at least 28 days prior to inclusion
Treatment with all substances potentially acting on sleep and mood must be constant since at least 28 days prior to inclusion
Written informed consent
Willingness and ability to participate in the trial

Exclusion criteria

Off label use of safinamide
Early PD or absence of PD fluctuations
Concomitant treatment with other MAO-B inhibitors (wash-out period: at least 14 days)
Atypical Parkinsonism
Severe known sleep-related breathing disorders with any specific treatment or severe known sleep-related breathing disorders (apnoea-hypopnea index score >30/h) with or without a specific treatment
Dementia (MoCA < 26)
Severe depression (BDI-II ≥ 29)
Other severe psychiatric symptoms such as active psychosis or major hallucinations
Any previous or concomitant severe medical conditions or clinical laboratory abnormality which, in the clinical judgement of the Investigators, does not allow patients' participation into the study
Moderate or severe hepatic impairment, any type of retinopathy and/or any pathology that is deemed to be a contraindication according to safinamide's SmPC
Any concomitant treatment not allowed or contraindicated in the safinamide SmPC
Women who are pregnant or breast feeding
Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.